Different phenotypes of monocytes in patients with new-onset mild acute pancreatitis.

Aim: To evaluate the numbers of different subsets of monocytes and their associations with the values of clinical measures in mild acute pancreatitis (MAP) patients.
Methods: The study included one group of 13 healthy controls and another group of 24 patients with new-onset MAP. The numbers of different subsets of monocytes were examined in these two groups of subjects by flow cytometry. The concentrations of plasma interleukin (IL)-10 and IL-12 were determined by cytometric bead array. The acute physiology and chronic health evaluation (APACHE) II scores of individual patients were evaluated, and the levels of plasma C-reactive protein (CRP) as well as the activities of amylase and lipase were measured.
Results: In comparison with that in the controls, significantly increased numbers of CD14+CD163-, CD14+CD163-MAC387+ M1 monocytes, but significantly reduced numbers of CD14+CD163+IL-10+ M2 monocytes were detected in the MAP patients ( P < 0.01 or P < 0.05). Furthermore, significantly higher levels of plasma IL-10 and IL-12 were observed in the MAP patients ( P < 0.01 for all). More importantly, the levels of plasma CRP were positively correlated with the numbers of CD14+CD163- ( R = 0.5009, P = 0.0127) and CD14+CD163-MAC387+ ( R = 0.5079, P = 0.0113) M1 monocytes and CD14+CD163+CD115+ M2 monocytes ( R = 0.4565, P = 0.0249) in the patients. The APACHE II scores correlated with the numbers of CD14+CD163+CD115+ ( R = 0.4581, P = 0.0244) monocytes and the levels of plasma IL-10 ( R = 0.4178, P = 0.0422) in the MAP patients. However, there was no significant association among other measures tested in this population.
Conclusion: Increased numbers of CD14+CD163- and CD14+ CD163-MAC387+ monocytes may contribute to the pathogenesis of MAP, and increased numbers of CD14+CD163+CD115+ monocytes may be a biomarker for evaluating the severity of MAP.
Competing Interests: Conflict-of-interest statement: The authors declare no financial or commercial conflicts of interest.